These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 17067910)

  • 1. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
    Majhail NS; Parks K; Defor TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy.
    Lewis ID; DeFor T; Weisdorf DJ
    Bone Marrow Transplant; 2000 Sep; 26(5):539-43. PubMed ID: 11019844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid.
    Wanko SO; Broadwater G; Folz RJ; Chao NJ
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):949-53. PubMed ID: 16920561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
    Majhail NS; Parks K; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2006 Dec; 38(11):765-8. PubMed ID: 17028622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
    Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
    Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients.
    Raptis A; Mavroudis D; Suffredini A; Molldrem J; Rhee FV; Childs R; Phang S; Barrett A
    Bone Marrow Transplant; 1999 Oct; 24(8):879-83. PubMed ID: 10516700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.